series-b
Stage
2009
Founded
3
Investors
About
Exicure is a clinical-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, with a current emphasis on hematologic diseases through its lead program burixafor (GPC-100).
Explore Exicure's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.